Imricor Medical SystemsASX:IMR +4.48%47 Days Payable is 54.77 as of Dec. 2025, which is 71% below its 10-year median of 186.00. GuruFocus rates ASX:IMR with a GF Score™ of 47/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 52.83% on this metric.
The historical rank and industry rank for Imricor Medical Systems's Days Payable or its related term are showing as below:
ASX:IMR'
s Days Payable Range Over the Past 10 Years
Min: 65.44 Med: 186 Max: 327.1
Current: 65.44
During the past 8 years, Imricor Medical Systems's highest Days Payable was 327.10. The lowest was 65.44. And the median was 186.00.
ASX:IMR's Days Payable is ranked worse than 52.83% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ASX:IMR: 65.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Imricor Medical Systems's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Days Payable distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Imricor Medical Systems's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a Days Payable of 54.77 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Imricor Medical Systems and its competitors. This is 71% below median its historical median of 186.00. Over the past decade, Imricor Medical Systems' Days Payable has ranged from 65.44 to 327.10. According to the industry distribution chart, Imricor Medical Systems ranks #420 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 52.8%.
Is Imricor Medical Systems' Days Payable too high?
Imricor Medical Systems' current Days Payable of 54.77 is 71% below median its 10-year median of 186.00. Over the past 10 years, this metric has ranged from a low of 65.44 to a high of 327.10. The Medical Devices & Instruments industry median Days Payable is 67.87. Imricor Medical Systems' value of 54.77 is 19.3% below this industry median. Based on the distribution chart, Imricor Medical Systems ranks #420 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Imricor Medical Systems has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #420 out of 795 companies for Days Payable. This places Imricor Medical Systems in the lower half of its industry. The industry median Days Payable is 67.87. Imricor Medical Systems' value of 54.77 is 19.3% below this benchmark. Historically, Imricor Medical Systems' own Days Payable has ranged from 65.44 to 327.10 over the past decade. While the company's 10-year median is 186.00 vs. the industry median of 67.87, Imricor Medical Systems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current Days Payable of 54.77 is 19.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current Days Payable is 54.77, which is 71% below median its own 10-year median of 186.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.87 — trading 1765% above its estimated fair value. The current Days Payable is 54.77, which is 71% below median its 10-year median of 186.00 and 19.3% below the Medical Devices & Instruments industry median of 67.87. Imricor Medical Systems' overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Days Payable is 54.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.87 is trading 1765% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
Days Payable: 54.77 (71% below median its 10-year median of 186.00)
GF Value™: A$0.10 vs. price of A$1.87 (1765% above fair value)
Industry Position: 19.3% below the Medical Devices & Instruments median (#420 of 795)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
47GF Score
Get the complete analysis for ASX:IMR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
